Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECOG 2809 MK-2206 plus bicalutamide in rising PSA high-risk prostate cancer
2011-003847-22Phase 2Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in prostate cancer (PCa) comparing Bicalutamide monotherapy with MK-2206 + bicalutamide combination therapy (2 arms). Primary endpoint: Proportion of patients with undetectable PSA at 44 weeks. Started Sep 2011; status: completed.
02
Drugs
MK-2206bicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2011-003847-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003847-22.